Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Pelli Skin Co. LLC manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct art units and 2 distinct examiners, reflecting the technical breadth of their pharmaceutical portfolio. This structure ensures that the 2 pending actions receive independent reviews from different officials, which can provide a more balanced perspective on the company's skin-related innovations. Utilizing multiple examiners can also help the company identify different potential paths to allowance.
The busiest examiner is MEYERS, ELIZABETH ANNE, who is responsible for 1 pending office action. Because the portfolio contains 2 pending actions, the workload is split equally across the 2 distinct examiners. Success in this portfolio depends on addressing the unique technical requirements of 2 distinct art units. Practitioners should be prepared to manage the specific procedural expectations of the 2 distinct art units while ensuring that the biotechnology and pharmaceutical claims are prosecuted with technical precision. This decentralized strategy requires careful coordination to maintain consistency across the company's active filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEYERS, ELIZABETH ANNE | 1 | 22.2% | +93.3% |
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18163153 | ANTIFUNGAL SOLUTION AND FOOT WIPE | MEYERS, ELIZABETH ANNE | — |
| 18163131 | LIDOCAINE SOLUTION AND FOOT WIPE | SCOTLAND, REBECCA LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18163153 | ANTIFUNGAL SOLUTION AND FOOT WIPE | MEYERS, ELIZABETH ANNE | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18163153 | ANTIFUNGAL SOLUTION AND FOOT WIPE | MEYERS, ELIZABETH ANNE | 1617 | §103§112DP | Non-Final OA | — | Pending | Feb 01, 2023 |
| 18163131 | LIDOCAINE SOLUTION AND FOOT WIPE | SCOTLAND, REBECCA LYNN | 1615 | §103§112 | Non-Final OA | — | Pending | Feb 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPelli Skin Co. LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Elizabeth Anne Meyers has the most, with 1 of Pelli Skin Co. LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
